anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a medicine for treating ankylosing spondylitis and a method thereof. The medicine is composed of the raw materials of rehmannia root, ginseng, aconite root, red sage root, eupolyphaga, Chinese wolfberry, dodder seed, kakuda figwort root, etc. The ginseng, the red sage root and eupolyphaga are prepared into fine powder, the rest is prepared into liquid extract through decocting, and after the fine powder and the liquid extract are mixed, the mixture is prepared into big honeyed pills. The medicine has antiinflammatory action and the function of regulating the immunity of a human body. The medicine can control the pathogenetic condition, recover the integral function, and can be used for treating rheumatic arthritis and rheumatoid arthritis. The medicine is one kind of safe and nontoxic traditional Chinese medicine preparation with outstanding curative effect.
When reacting a 2,2,2-trichloro-1-(N-hydrocarbylpyrryl-2)-ethanol in solution with a cyanating reagent under basic conditions, advantages are achieved by performing the reaction in an aqueous reaction medium containing at least 3 equivalents of calcium hydroxide per mole of the 2,2,2-trichloro-1-(N-hydrocarbylpyrryl-2)-ethanol used in the reaction. Good yields are achieved in short reaction times. Large excesses of cyanating reagents are not required. It is unnecessary to add components to the reaction vessel on a periodic basis in order to achieve good yields. And it is possible to isolate the desired product in the form of a calcium salt by a facile procedure. This enables the desired product to be formed by acidification of the isolated calcium salt without the hazards of toxic HCN generation.
Neurology deals with organic diseases of the muscles, the peripheral nerves of the trunk and extremities, and the central nervous system (spinal cord, brain, stem, cerebellum, and cerebrum). Diseases that lead to dysfunction of these structures can cause both physical and cognitive problems. Therefore, neurological diseases can particularly impair personal mobility through both physical limitations and cognitive deficits. Many of the diseases show a significant increase in frequency with age.Physical impairments in mobility primarily manifest as gait disorders. These are found to a relevant extent in two-thirds of people older than 80 years of age and are a common cause of falls, often with considerable sequelae. Driving a car can have negative effects, for example, on reaction speed, braking power, and looking over the shoulder. Parkinson's disease as well as paralysis and sensory disorders in the context of polyneuropathies can be responsible for this.Driving a car is an obvious compensatory mechanism with respect to impaired walking ability. However, the cause of many diseases that affect the fitness to walk lies in the central nervous system, often in the area of the cerebrum. Consequently, cognitive deficits manifest themselves in addition to physical ones, which further restrict mobility through the loss of the fitness to drive. Neurological diseases typical of old age that limit mobility in this way include Parkinson's disease and circulatory disorders of the brain. In addition, epileptic seizures occur more frequently in old age as a symptom of other diseases.
Select phytoestrogen pharmaceutical compositions and methods of use for preventing or reducing one or more symptoms associated with pre menopause, menopause, and/or post menopause are described herein. These select phytoestrogen formulations are composed only of two or more plant-derived estrogenic molecules and/or their structural analogues and exhibit binding preference to ERβ over ERα and agonist activity in the brain. These ERβ-selective phytoestrogen formulations cross the blood-brain-barrier and promote estrogen-associated neurotrophism and neuroprotection mechanisms in the brain, without activating proliferative mechanisms in the reproductive tissues and are therefore devoid of other estrogen-associated problematic aspects. The formulations can be administered enterally, transdermally, transmucosally, intranasally or parenterally. The formulations preferably contain combinations of compounds, and can be formulated for daily, sustained, delayed or weekly/monthly administration. In a preferred embodiment, these are administered to women who are in menopause or post menopausal, most preferably early in menopausal.
Monitor vital signs prior to the start of the infusion and with every dose increase.

Administer AURLUMYN as a continuous intravenous infusion over 6 hours each day for up to a maximum of 8 consecutive days.

Start the initial infusion on day 1 at a rate of 0.5 ng/kg/minute and increase in increments of 0.5 ng/kg/minute every 30 minutes according to tolerability up to 2 ng/kg/minute. Dosage is based on actual patient body weight (kg). Repeat dose titration steps on day 2 and day 3. From day 4 onward, start the infusion at the highest tolerated dose from the previous day, and adjust the rate as needed, based on tolerability.

Adverse reactions such as headache, flushing, jaw pain, myalgia, nausea, and vomiting may be dose-limiting. If dose-limiting adverse reactions occur that cannot be tolerated by the patient, then decrease the dose in a stepwise manner by 0.5 ng/kg/min every 30 minutes, until a tolerated dose is reached. If a dose-limiting adverse reaction occurs during administration of AURLUMYN at the starting dose, the infusion should be discontinued, and re-initiation of the infusion can be attempted after the event has resolved or been treated. If infusion is stopped at any point for a dose-limiting adverse event, infusion can be reinitiated at a previously tolerated dose/infusion rate once the event has resolved. The maximum tolerated dose should be maintained for the remaining 6-hour daily infusion.
Objective: To explore the clinical manifestations and genotype of an infant with hyperuricemia, pulmonary hypertension, renal failure in infancy, and alkalosis syndrome (HUPRAS). Methods: Clinical data of the patient were collected. Peripheral blood samples from the patient and his parents were acquainted for whole exome sequencing. The filtrated variants were verified by Sanger sequencing. The pathogenicity of the variants was predicted by bioinformatic tools. Results: The patient is a male infant of 6 months old, carrying two missense variants in the SARS2 allele: a paternal inherited c.1205G>A (p. Arg402His) and a maternal inherited c.680G>A (p. Arg227Gln). The two variants were in extremely low population frequencies. The pathogenetic prediction tools categorized them as deleterious. Arg402 and Arg227 were highly conserved in evolution. The variants led to changes in the hydrogen bonds and hydrophobicity of seryl-tRNA synthetase encoded by SARS2. Conclusions: c.1205G>A (p. Arg402His) and c.680G>A (p. Arg227Gln) are the possible causative variants of the HUPRA syndrome.
Patients with lung or esophageal cancer undergoing conventionally-fractionated radiation therapy. Interventions to be administered include: Imaging Biomarkers using Volumetric CT Scans, Pulmonary using Pulmonary Function Test \& 6Minute Hall Walk, Imaging using Cardiac MRI, Specimen Collection using Blood Draws.
We will retrospectively collect data from adults (≥18 years) admitted to a participating ICU who are invasively mechanically ventilated for more than 12 hours. We will include data from patients admitted with a confirmed diagnosis of acute respiratory failure due to COVID-19 infection.
Patients 65 years and over, particularly those with hypertension, may be at increased risk for developing hypotension while undergoing anesthesia with Bupivacaine Hydrochloride injection.

In clinical studies of bupivacaine, elderly patients reached the maximal spread of analgesia and maximal motor blockade more rapidly than younger adult patients.

Differences in various pharmacokinetic parameters have been observed between elderly and younger adult patients [see Clinical Pharmacology (12.3)].

This product is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. Elderly patients may require lower doses of Bupivacaine Hydrochloride injection.
Nasal fractures are one of the most incidental of facial traumas. Regression of nasal edema is necessary so that surgical reduction of the fracture can be performed. It is known that photobiomodulation (PBM) reduces pain, edema and modulates inflammation. Regression of edema in a shorter time may decrease hospitalization time, decreasing hospital costs. However, there are no well-designed clinical studies on this subject. Therefore, the objective of this study will be to evaluate if PBM is able to reduce edema in the region of fractured nasal bones prior to nasal reduction and nasal packing, in order to reduce the patient's ability to go through surgery. Thirty-six patients diagnosed with a (primary) nasal fracture admitted to the Mandaqui Hospital Complex whose trauma occurred in the last 48 hours will be randomly divided into: G1- (control) (n = 18). The control group will be submitted to the standard hospital treatment: standard drug therapy (50mg diclofenac sodium - 5 days, 8 / 8h orally and 500mg dipyrone - 5 days, 6 / 6h , orally). Tylex 30mg orally will be given as rescue medication. In this group there will be simulation of the use of the mask. G2- LED group (n = 18) - The standard hospital treatment will be performed + LED nasal mask (3 points on each side of the nose), λ = 830nm, radiant exposure of 9.7 Joules J / cm2 for 10 minutes. Treatment will be performed at patient admission (up to 24 hours after nasal trauma), and at intervals explained below, for approximately 08 days after hospital admission. The main variable will be the edema evaluated by the same researcher and with the same technique. Secondary variables will be pain (visual analogue scale - VAS), temperature, rescue medication count, serum C-reactive protein and systemic inflammatory cytokines (TNF-α, interleukin-1 (IL-1), IL-6, IL-8 and IL- nasal fossa and saliva. All evaluations will be performed at baseline (T0) up to 48 hours after trauma, aiming at equivalence in the inflammatory process, (T1) 96h after trauma and (T2) 192h after trauma. Afterwards, the LED or its placebo will also be applied. The questionnaire to assess the impact of treatment on quality of life will be applied at the baseline and after 8 days. Adverse effects will be recorded and reported. If the data is normal, they will be submitted to Student's t-test. The data will be presented by their means ± SD and the value of p will be set at 0.05.
Preoperative vacuum-assisted biopsy was performed within 10 days before final surgery. The tumor were excised almost.
A film-coated tablet/granules comprising core containing pyridylpyrimidine compound (c1), or its salt (25 - 80 wt.%) (preferably imatinib or its monomethanesulfonate salt) and at least one filler-binder, and optionally other additives, is produced by pressing the starting materials, in which prior to pressing at least one of them has been dry-granulated (preferably compressed or compacted). Independent claims are included for the following: (1) production of the film-coated tablet or granules involving producing the tablet cores and the granules by pressing of the starting materials and, prior to pressing of the starting materials, at least one of them is dry-granulated (preferably compressed or compacted); and coating the resulting tablet cores and optionally granules with a film, where the starting materials contain the compound (c1) and at least one compound acting as filler-binder, and optionally other additives in the mixture, and the compound (c1) is present in an amount of 25 - 80 wt.%; (2) the tablet cores and granule cores which are not provided with a film coating and which are used as intermediates for the production of film-coated tablets and film-coated granules; and (3) powder mixtures which are used as intermediates for the production of the tablet cores and granule cores. ACTIVITY : Cytostatic. No biological data given. MECHANISM OF ACTION : Tyrosine kinase inhibitor. No biological data given.
FIELD: medicine.SUBSTANCE: present group of inventions relates to the use of a plant extract of Galeopsis tetrahit or a composition containing it for the stimulation of hair growth. The cosmetic use of the plant extract extracted with an aqueous-alcohol solvent from an above-ground part of Galeopsis tetrahit species is proposed for the stimulation of hair growth in an individual. The cosmetic use of the composition containing the plant extract extracted with an aqueous-alcohol solvent from an above-ground part of Galeopsis tetrahit species and a physiologically acceptable carrier is proposed for the stimulation of hair growth in an individual, where the amount of the plant extract in the composition is from 0.0001 to 10 wt. %. The use of the plant extract extracted with an aqueous-alcohol solvent from an above-ground part of Galeopsis tetrahit species is proposed for the treatment of androgenic alopecia or telogen alopecia. The use of the composition containing the plant extract from an above-ground part of Galeopsis tetrahit extracted with an aqueous-alcohol solvent and a physiologically acceptable carrier is proposed for the treatment of androgenic alopecia or telogen alopecia, where the amount of the plant extract in the composition is from 0.0001 to 10 wt. %.EFFECT: above-described use of the extract or composition based on it is effective for the stimulation of hair growth in an individual for the treatment of androgenic alopecia or telogen alopecia.18 cl, 12 dwg, 3 tbl, 8 ex
Described is a method of manufacturing microcapsules from biodegradable polymers, the method using biodegradable solvents and producing microcapsules which are free from toxic solvent residues. The solvents used include simple esters made from a C1-C5 alcohol and a C1-C5 monocarboxylic acid, as well as mixtures of such esters, and the solvent can also contain a C1-C5 alcohol. Both water-soluble and water-insoluble active substances can be incorporated in the microcapsules. Water-soluble active substances such as drugs, peptides, proteins, enzymes and vaccins are preferably dispersed as an aqueous solution in the polymer solution. The microcapsules are produced by spraying a solution, suspension or water-in-oil dispersion of active substances and biodegradable polymers. The method is suitable for use in the manufacture of drug, vaccin and enzyme preparations.
Currently, three oral nucleoside/tides analogues (NUC), including entecavir(ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF), are available as the first line of treatment option for chronic hepatitis B (CHB) in Taiwan. Among them, TDF exhibits a greater decline of cholesterol, High-density lipoprotein(HDL), and low-density lipoprotein (LDL) levels than entecavir, while the impact of such general lipid-lowering effects on the risk of atherosclerotic cardiovascular diseases (ASCVD) remains unclear. For metabolic features, the evidence comes from HIV patients treated with TDF or TAF containing anti-retroviral therapy (ART). In one study revealed that a 0.45 kg/m2 increase of body mass index (BMI) and a 13% of increase in ASCVD risk score after switching from TDF-containing to TAF-containing ART. Weight gain after starting ART has been reported to associate with lower mortality in initial under-weight or normal-weight HIV patients. However, a study compared the efficacy and safety of dolutegravir/TAF/emtricitabine, dolutegravir/TDF/emtricitabine, and EFV/TDF/emtricitabine and revealed that patients receiving TAF and TDF containing regimens significantly increased body weight. The subsequent body composition analysis showed weight gain mainly resulted from increased lean muscle and fat of trunk and limb. A previous study also showed that the ART-associated increase in muscle area, regardless of regimen, is likely a reflection of increased fat within the muscle that may associate with weakness of muscle strength, risk of fall, and a decline of physical activities.

Overall, in HIV-infected patients, TAF-containing regimens had been shown to increase body weight resulting from increased fat and muscle of trunk and limb. However, it remains unknown whether all these findings in HIV infected patients could be similarly observed in CHB patient receiving TAF therapy, which is commonly encountered in Asia-Pacific region. Moreover, the mechanisms underlying these changes are still unclear. The long-term clinical impact of the BW gain and associated metabolic derangement is also unknown.
A method for producing ACE Inhibitor peptides from a protein source or plasma is disclosed. The method utilizes proteolysis by intestinal, blood-circulating, or membrane-bound proteases. The initial synthesis step could require obtaining a protein source either from a human or animal. A protease is added to either a given plasma protein or plasma and incubated. Following incubation, the protease activity must be quenched using a protease inhibitor to inactivate the protease. After incubation with protease inhibitor, the solution will contain a mixture of bioactive ACE inhibitory peptides and inert peptides. This mixture may be purified to select for the ACE inhibitory peptides through centrifugation. The mixture may also be sterilized to remove any microbial contaminants. The ACE inhibitory peptides can be mixed with protein powders, incorporated into baked good and put into other food products to provide food products with the added benefit of lowering blood pressure.
Recreational users of prescription opioids. Participants in this arm received the 3 interventions (0, 15, and 30 mg oxycodone) at random.
<P>PROBLEM TO BE SOLVED: To provide a human protein having a hydrophobic domain, to provide a cDNA encoding the same, to provide an expression vector for the cDNA and to provide a eucaryotic cell expressing the cDNA.  <P>SOLUTION: The protein comprises any of an amino acid sequences represented by sequence number 1 to sequence number 10. The DNA encoding the protein, e.g. the cDNA comprising a base sequence represented by sequence number 11 to sequence number 20 is provided. The expression vector for the cDNA is provided. The eucaryotic cell expressing the cDNA is provided. The protein and the eucaryotic cell expressing the protein can be obtained by expressing a recombinant of the cDNA encoding the human protein having the hydrophobic domain.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Novel methods and dental compositions for treating dental structures, such as teeth and subgingival structures, are disclosed. Uniquely, the dental compositions contain metal complexes which are characterized as having an unique aqueous proton induced dissociation property represented by a sigmoidally-shaped curve on a cartesian coordinate plot of the negative log of the metal ion concentration versus the negative log of the hydrogen ion concentration. This unique dissociation property enables the metal complexes to release therapeutic metal ions in the oral cavity for forming metal coordination complexes or salts within the dental structures. The formation of such complexes or salts within the dental structures is particularly effective and highly resistant to enzymatic degradation associated with microbial activity. Also, the metal ions of this invention are highly effective in inactivating the enzymes secreted by microbes in the oral cavity to further attenuate the disintegration process. The metal complexes of the new and vastly improved dental compositions advantageously are highly soluble yet readily dissociable at pH ranges normally encountered in the human mouth. As the active ingredient, the dental compositions contain a monometal complex of a multivalent heavy metal ion and a polyfunctional organic ligand in a ratio of about 1:1. An example of a dental composition employed is disodium monocopper(II) citrate in an amount of about 4 mg./ml., as copper, in a liquid vehicle having a pH of about 7.
The study is a phase I, open-label, dose escalation single center study in patients with solid tumors. The study will investigate safety, tolerability and Maximal Tolerated Dose as primary end-points of an irinotecan tablet given as single agent or in combination with oral capecitabine. Secondary end-points are pharmacokinetics and preliminary anti-tumor response.

Cohorts of 3 patients will be treated on selected dose level with oral irinotecan in order to identify Dose Limiting Toxicity (DLT) and Maximal Tolerated Dose (MTD). Totally 12 subjects will be treated at the MTD level. Patients will receive irinotecan tablets once daily in the morning for 14 consecutive days within 3 week treatment cycles. As an extension trial totally 12 subjects will be treated with oral irinotecan in combination with oral capecitabine. Patients treated in combination therapy will receive irinotecan tablets once daily in the morning for 14 consecutive days in combination with capecitabine dosed twice daily for 14 consecutive days within 3 week treatment cycles.
PURPOSE:To obtain the titled hybridized cellular strain in high purity and yield, by hybridizing a human acute leukemic cellular strain treated with a proteinic synthetic inhibitor, etc. with a human T cell stimulated with a mitogen, etc. in the presence of a hybridization promotor. CONSTITUTION:A human acute leukemic cellular strain, e.g. CEM or TALL, is treated with a proteinic synthetic inhibitor, e.g. emetin hydrochloride, or further with an RNA synthetic inhibitor, e.g. actinomycin D. On the other hand, a human T cell is stimulated with a nitrogen, e.g. phytohemagglutinin-P, or an antigen, and both are hybridized in the presence of a hybridization promotor, e.g. polyethylene glycol. Only the hybridized cells are then separated to give the aimed hybridized cell of the human T cell, capable of subculture and producing lymphokine. The mixing ratio between the human T cell and the human acute leukemic cellular strain is in the range of (1:1)-(20:1), preferably (2:1)-(15:1).
The invention provides a traditional Chinese medicine oral liquid for treating chicken infectious laryngotracheitis and a preparation method thereof. The traditional Chinese medicine oral liquid comprises following components by weight: 1-3 parts of honeysuckle flower, 1-3 parts of radix scutellaria, 1-3 parts of ginger processed pinellia, 1-2 parts of dried orange peel, 0.5-1 parts of radix sophorae tonkinensis, 1-3 parts of poria cocos and 1-2 parts of liquorice. The traditional Chinese medicine oral liquid is prepared by a water-boiling and digesting method. The traditional Chinese medicine oral liquid is constituted reasonably from traditional Chinese medicines, and has significant effects of clearing away heat and drying dampness, preventing phlegm from forming and stopping coughing, regulating the circulation of qi and regulating the middle warmer. The traditional Chinese medicine oral liquid provides an effective medicine for treating the chicken infectious laryngotracheitis for the poultry industry. The traditional Chinese medicine oral liquid has characteristics of taking convenience, rapid effectiveness, reliable curative effects, no medicine residual, difficult generation of drug resistance, no side effects and no toxic effects. The preparation method is simple and is suitable for requirements of large-scale industrial production.
Study subjects will be randomized to receive either latanoprost once daily or bimatoprost once daily for 6 weeks, after which they will be crossed over to the other medication for another 6 weeks. The IOP-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.
NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.